Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A H Nelson

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1998
SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytesA M Badger, M N Cook, M W Lark, et al.
Anesthesiology|October 1, 1992
ST segment depression during labor and deliveryJ P Mathew, L A Fleisher, J A Rinehouse, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1996
Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone ratsF C Barone, A H Nelson, E H Ohlstein, et al.
Journal of Cardiovascular Pharmacology|October 6, 2001
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunctionR N Willette, K M Anderson, A H Nelson, et al.
British Journal of Pharmacology|October 30, 2001
Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expressionV Y Wong, N J Laping, A H Nelson, et al.
Journal of Dairy Science|December 2, 2014
Allometric comparison of Georgia dairy heifers on farms and at youth showsD S White, K J Duberstein, J L Fain Bohlen, et al.
Cardiovascular Research|May 30, 2001
Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone ratsF C Barone, R W Coatney, S Chandra, et al.
Circulation|September 12, 2001
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunctionT M Behr, S S Nerurkar, A H Nelson, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1998
SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytesA M Badger, M N Cook, M W Lark, et al.
Anesthesiology|October 1, 1992
ST segment depression during labor and deliveryJ P Mathew, L A Fleisher, J A Rinehouse, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1996
Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone ratsF C Barone, A H Nelson, E H Ohlstein, et al.
Journal of Cardiovascular Pharmacology|October 6, 2001
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunctionR N Willette, K M Anderson, A H Nelson, et al.
British Journal of Pharmacology|October 30, 2001
Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expressionV Y Wong, N J Laping, A H Nelson, et al.
Journal of Dairy Science|December 2, 2014
Allometric comparison of Georgia dairy heifers on farms and at youth showsD S White, K J Duberstein, J L Fain Bohlen, et al.
Cardiovascular Research|May 30, 2001
Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone ratsF C Barone, R W Coatney, S Chandra, et al.
Circulation|September 12, 2001
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunctionT M Behr, S S Nerurkar, A H Nelson, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Pageof 7